-+ 0.00%
-+ 0.00%
-+ 0.00%

Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award

Barchart·10/06/2026 07:19:00
Listen to the news

WESTLAKE VILLAGE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that ZORYVE® (roflumilast) cream 0.15% was presented with the 2026 “Best Prescription Skin Solution” Award by Marie Claire magazine. The magazine created this award category as part of its Marie Claire US Beauty Awards to recognize medical innovation in bringing advanced skin solutions to consumers. ZORYVE is the first prescription medication to win this award and is being recognized for the innovation it offers to people with mild to moderate atopic dermatitis (eczema) 6 years of age and older.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.